Everett Harris & Co. CA Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Everett Harris & Co. CA acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,647 shares of the medical equipment provider’s stock, valued at approximately $2,552,000.

A number of other institutional investors also recently modified their holdings of the company. DV Equities LLC bought a new position in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Monetary Solutions Ltd bought a new stake in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth about $31,000. Elevation Wealth Partners LLC raised its holdings in shares of Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares during the last quarter. Finally, Cornerstone Financial Management LLC bought a new position in Zimmer Biomet in the 4th quarter valued at about $37,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Robert W. Baird set a $104.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Zacks Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Citigroup dropped their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $104.42.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $100.52 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The stock has a market cap of $19.17 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 3.17 and a beta of 0.45. The stock has a fifty day moving average of $91.51 and a 200-day moving average of $90.54.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the firm posted $2.07 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.